Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...

The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

BayCare's Morton Plant Hospital in Clearwater recently completed the world's first TAV-in-TAV as part of a study called RESTORE.TAV-in-TAV is for people who have undergone a prior TAVR procedure, but ...